MeiraGTx to Participate in Upcoming Investor Conferences
21 April 2023 - 7:00AM
MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically
integrated, clinical stage gene therapy company, today announced
that Alexandria Forbes, Ph.D., President and Chief Executive
Officer, will participate in the following investor conferences:
- Chardan's Virtual 7th Annual
Genetic Medicines and Cell Therapy Manufacturing
Summit
Corporate presentation: Monday, April 24, 2023, at 2:30 p.m.
ET
Panel Discussion: “Gene Therapy: Positioning for CMC
Success at Every Stage” –
Tuesday, April 25, 2023, at 12:00 p.m. ET
- BofA Securities 2023 Healthcare
Conference
Corporate Presentation: Wednesday, May 10, 2023, at 2:35 p.m.
PT
- RBC Capital Markets 2023
Global Healthcare Conference
Corporate Presentation: Wednesday, May 17, 2023, at 10:00 a.m.
ET
A live webcast of the corporate presentations will be available
on the Investors page of the Company’s website at
www.investors.meiragtx.com. Replays will be available for
approximately 30 days following the presentation dates.
About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical
stage gene therapy company with six programs in clinical
development and a broad pipeline of preclinical and research
programs. MeiraGTx has core capabilities in viral vector design and
optimization and gene therapy manufacturing, and a transformative
gene regulation platform technology that allows precise, dose
responsive control of gene expression by oral small molecules with
dynamic range that can exceed 5000-fold. Led by an experienced
management team, MeiraGTx has taken a portfolio approach by
licensing, acquiring, and developing technologies that give depth
across both product candidates and indications. MeiraGTx’s initial
focus is on three distinct areas of unmet medical need: ocular,
including both inherited retinal diseases as well as large
degenerative ocular diseases, neurodegenerative diseases and severe
forms of xerostomia. Though initially focusing on the eye, central
nervous system, and salivary gland, MeiraGTx plans to expand its
focus to develop additional gene therapy treatments for patients
suffering from a range of serious diseases.
For more information, please visit www.meiragtx.com.
ContactsInvestors:MeiraGTxInvestors@meiragtx.com
Media:Jason Braco, Ph.D.LifeSci
Communicationsjbraco@lifescicomms.com
MeiraGTx (NASDAQ:MGTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
MeiraGTx (NASDAQ:MGTX)
Historical Stock Chart
From Jul 2023 to Jul 2024